ImmuCell Corp
ICCC
NASDAQ
Biotechnology
$10.05
USD
-0.85 (-7.80%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $100.42M
Volume 92.0K
Revenue
$29.93M
TTM
+9.6%
YoY
Gross Margin
43%
TTM
+29.2%
YoY
Net Income
$-545,403
TTM
-100.7%
YoY
Operating Cash Flow
$4.47M
TTM
+195.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 8.1 | 6.4 | 5.5 | 7.6 | 10.4 |
YoY Growth | +11.2% | +17.8% | -8.4% | -1.6% | +28.4% |
Cost of Revenue | 4.7 | 3.6 | 3.1 | 4.7 | 5.7 |
Gross Profit | 3.4 | 2.8 | 2.4 | 2.9 | 4.7 |
Selling, General & Administrative | 1.5 | 1.4 | 1.6 | 2.2 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.2 | 2.2 | 2.3 | 3.0 | 2.7 |
Operating Income | 1.1 | 0.6 | 0.0 | -0.1 | 2.0 |
EBITDA | 1.8 | 1.2 | 0.7 | 0.6 | 2.5 |
Other Income / Expense | 0.3 | -0.1 | -0.2 | -2.8 | -0.0 |
Total Other Income / Expense | 0.3 | -0.1 | -0.2 | -2.8 | -0.0 |
Income Before Income Taxes | 1.4 | 0.5 | -0.1 | -2.8 | 2.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 1.4 | 0.5 | -0.1 | -2.8 | 1.9 |
Consolidated Net Income / Loss | 1.4 | 0.5 | -0.1 | -2.8 | 1.9 |
Net Income Attributable to Common Shareholders | 1.4 | 0.5 | -0.1 | -2.8 | 1.9 |
Basic EPS | $0.16 | $0.06 | -$0.02 | -$0.31 | $0.21 |
Diluted EPS | $0.16 | $0.06 | -$0.02 | -$0.31 | $0.21 |
Basic Shares Outstanding | 9.0M | 9.0M | 9.0M | 9.0M | 9.0M |
Diluted Shares Outstanding | 9.0M | 9.0M | 9.0M | 9.0M | 9.0M |